"BRCA1 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). It contains an N-terminal RING FINGER DOMAIN and is a PROTEIN PHOSPHATASE 1 regulatory subunit. In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)
| Descriptor ID |
D019313
|
| MeSH Number(s) |
D12.776.313.125 D12.776.624.776.100 D12.776.660.100 D12.776.744.100 D12.776.930.137
|
| Concept/Terms |
BRCA1 Protein- BRCA1 Protein
- Breast Cancer Type 1 Susceptibility Protein
- Breast Cancer 1 Protein
- Ring Finger Protein 53
- BRCA1 Gene Product
- Breast Cancer 1 Gene Product
|
Below are MeSH descriptors whose meaning is more general than "BRCA1 Protein".
Below are MeSH descriptors whose meaning is more specific than "BRCA1 Protein".
This graph shows the total number of publications written about "BRCA1 Protein" by people in this website by year, and whether "BRCA1 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "BRCA1 Protein" by people in Profiles.
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early?breast cancer. Ann Oncol. 2022 Dec; 33(12):1250-1268.
-
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021 11; 157:415-423.
-
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021 10; 163(1):41-49.
-
Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 05 03; 4(5):e217728.
-
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
-
Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis. Biochim Biophys Acta Rev Cancer. 2021 01; 1875(1):188482.
-
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast. Appl Immunohistochem Mol Morphol. 2020 10; 28(9):661-668.
-
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020 11; 159(2):491-497.
-
BRCA1 promoter hypermethylation in human placenta: a hidden link with ß-hCG expression. Carcinogenesis. 2020 07 10; 41(5):611-624.
-
ß-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue. Carcinogenesis. 2019 Nov 25; 40(11):1415-1426.